Codexis Company Profile (NASDAQ:CDXS)

About Codexis (NASDAQ:CDXS)

Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Industry, Sector and Symbol:

Sector: Industrial Products
Industry: Biotechnology & Medical Research
Sub-Industry: Biotechnology
Symbol: NASDAQ:CDXS
CUSIP: 19200510
Web: www.codexis.com

Capitalization:

Market Cap: $280.28 million
Outstanding Shares: 48,324,000

Average Prices:

50 Day Moving Avg: $5.43
200 Day Moving Avg: $4.93
52 Week Range: $3.60 - $5.98

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -25.22
P/E Growth: -1.02

Sales & Book Value:

Annual Revenue: $43.16 million
Price / Sales: 6.49
Book Value: $0.63 per share
Price / Book: 9.21

Profitability:

EBIDTA: ($15,160,000.00)
Net Margins: -40.70%
Return on Equity: -83.39%
Return on Assets: -45.44%

Debt:

Current Ratio: 3.06%
Quick Ratio: 2.99%

Misc:

Average Volume: 155,758 shs.
Beta: -1.37
Short Ratio: 14.32

Frequently Asked Questions for Codexis (NASDAQ:CDXS)

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.13) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.13). The company earned $10.30 million during the quarter, compared to analyst estimates of $9.61 million. Codexis had a negative return on equity of 83.39% and a negative net margin of 40.70%. The firm's revenue was down 35.6% on a year-over-year basis. During the same quarter last year, the business posted $0.12 earnings per share. View Codexis' Earnings History.

When will Codexis make its next earnings announcement?

Codexis is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Codexis.

Where is Codexis' stock going? Where will Codexis' stock price be in 2017?

4 equities research analysts have issued twelve-month target prices for Codexis' stock. Their predictions range from $5.50 to $8.00. On average, they expect Codexis' stock price to reach $6.94 in the next twelve months. View Analyst Ratings for Codexis.

Who are some of Codexis' key competitors?

Some companies that are related to Codexis include Inovio Pharmaceuticals (INO), PDL BioPharma (PDLI), Celyad SA (CYAD), Kala Pharmctls (KALA), Adamas Pharmaceuticals (ADMS), Voyager Therapeutics (VYGR), Mesoblast Limited (MESO), Cara Therapeutics (CARA), Agenus (AGEN), Arbutus Biopharma Corporation (ABUS), Corvus Pharmaceuticals (CRVS), Novavax (NVAX), NewLink Genetics Corporation (NLNK), Idera Pharmaceuticals (IDRA), Concert Pharmaceuticals (CNCE), Puretech Health PLC (PRTC), Celldex Therapeutics (CLDX) and Protagonist Therapeutics (PTGX).

Who are Codexis' key executives?

Codexis' management team includes the folowing people:

Bernard J. Kelley, Chairman of the Board
John J. Nicols, President, Chief Executive Officer, Director
Gordon T. Sangster, Chief Financial Officer, Senior Vice President
Douglas T. Sheehy J.D., Executive Vice President, Chief Administrative Officer, General Counsel, Secretary
Michael Douglas Arthur Aldridge, Senior Vice President - Corporate & Strategic Development
James Lalonde, Senior Vice President, Research & Development
Thomas R. Baruch J.D., Chairman Emeritus
Pam P. Cheng, Director
Kathleen Sereda Glaub, Director
Patrick Y. Yang, Director

Who owns Codexis stock?

Codexis' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (10.99%), Prescott Group Capital Management L.L.C. (4.24%), Vanguard Group Inc. (3.67%), Baillie Gifford & Co. (3.03%), FMR LLC (2.56%) and William Blair Investment Management LLC (2.26%). Company insiders that own Codexis stock include Bernard J Kelley, Dennis P Wolf, James Lalonde, Patrick Y Yang, Ventures Fund Vii LP Vivo, Ventures Vii Affiliates F Vivo and Vivo Ventures Vii, Llc. View Institutional Ownership Trends for Codexis.

Who sold Codexis stock? Who is selling Codexis stock?

Codexis' stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, FMR LLC, Arrowstreet Capital Limited Partnership and New York State Common Retirement Fund. View Insider Buying and Selling for Codexis.

Who bought Codexis stock? Who is buying Codexis stock?

Codexis' stock was purchased by a variety of institutional investors in the last quarter, including Prescott Group Capital Management L.L.C., Vanguard Group Inc., Baillie Gifford & Co., First Light Asset Management LLC, State Street Corp, Blair William & Co. IL, William Blair Investment Management LLC and Northern Trust Corp. View Insider Buying and Selling for Codexis.

How do I buy Codexis stock?

Shares of Codexis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Codexis' stock price today?

One share of Codexis stock can currently be purchased for approximately $5.80.

MarketBeat Community Rating for Codexis (NASDAQ CDXS)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		101 (Vote Outperform)
Underperform Votes:		119 (Vote Underperform)
Total Votes:		220

MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Codexis (NASDAQ:CDXS) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	1 Hold Rating, 3 Buy Ratings
Consensus Rating:	Buy (Score: 2.75)
Consensus Price Target:	$6.94 (19.61% upside)

Analysts' Ratings History for Codexis (NASDAQ:CDXS)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
8/11/2017	HC Wainwright	Set Price Target	Buy	$8.00	High
5/31/2017	Jefferies Group LLC	Initiated Coverage	Buy -> Buy	$8.00	High
1/26/2017	First Analysis	Downgrade	Overweight -> Equal Weight	$5.50	N/A
1/4/2017	Ladenburg Thalmann Financial Services	Upgrade	Neutral -> Buy	$6.25	N/A

(Data available from 9/20/2015 forward)

Earnings History for Codexis (NASDAQ:CDXS)

Earnings by Quarter for Codexis (NASDAQ:CDXS)

Earnings History by Quarter for Codexis (NASDAQ CDXS)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/6/2017		($0.17)					N/A
8/9/2017	Q2 2017	($0.13)	($0.13)	$9.61 million	$10.30 million	View	Listen
5/9/2017	Q1 2017	($0.15)	($0.18)	$9.23 million	$7.97 million	View	Listen
3/9/2017	Q4 2016	($0.11)	($0.12)	$9.15 million	$10.00 million	View	Listen
11/8/2016	Q3	($0.14)	$0.06	$7.41 million	$14.90 million	View	Listen
8/9/2016	Q216	$0.03	$0.12	$15.10 million	$16.00 million	View	Listen
5/9/2016	Q1	($0.15)	($0.11)	$7.49 million	$8.00 million	View	Listen
3/3/2016	Q4	($0.04)	$0.02	$11.63 million	$11.60 million	View	N/A
11/4/2015	Q315	($0.11)	$0.13	$8.85 million	$17.40 million	View	Listen
8/11/2015	Q215	($0.14)	($0.14)	$7.34 million	$6.02 million	View	Listen
5/7/2015	Q115	($0.12)	($0.14)	$8.00 million	$6.80 million	View	Listen
3/3/2015	Q414	$0.01	$0.07	$13.30 million	$14.20 million	View	Listen
11/4/2014	Q314	($0.06)	($0.05)	$9.00 million	$7.47 million	View	Listen
8/6/2014	Q214	($0.15)	($0.22)	$8.50 million	$6.60 million	View	Listen
5/7/2014	Q114	($0.10)	($0.17)	$10.00 million	$7.10 million	View	Listen
3/11/2014	Q413	($0.21)	($0.26)	$10.00 million	$9.50 million	View	Listen
11/12/2013	Q313	($0.31)	($0.24)	$8.50 million	$3.90 million	View	Listen
8/9/2013	Q2 2013	($0.28)	($0.33)	$9.00 million	$6.97 million	View	Listen
5/7/2013	Q1 2013	($0.36)	($0.25)	$7.63 million	$11.48 million	View	Listen
2/27/2013	Q4 2012	($0.34)	($0.41)	$9.33 million	$7.90 million	View	Listen
11/7/2012	Q312	($0.15)	($0.06)	$25.88 million	$26.34 million	View	N/A
8/9/2012		($0.18)	($0.15)			View	N/A
5/10/2012		($0.15)	($0.21)			View	N/A
2/7/2012		($0.11)	($0.15)			View	N/A
11/1/2011		($0.08)	($0.08)			View	N/A
7/28/2011		($0.10)	($0.14)			View	N/A
5/5/2011		($0.07)	($0.10)			View	N/A
2/3/2011		($0.06)	($0.01)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Codexis (NASDAQ:CDXS)

2017 EPS Consensus Estimate: ($0.32)
2018 EPS Consensus Estimate: ($0.13)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	1	($0.10)	($0.10)	($0.10)
Q2 2017	2	($0.14)	($0.12)	($0.13)
Q3 2017	2	($0.17)	($0.14)	($0.16)
Q4 2017	1	$0.07	$0.07	$0.07
Q1 2018	1	($0.13)	($0.13)	($0.13)
Q2 2018	1	($0.13)	($0.13)	($0.13)
Q3 2018	1	($0.07)	($0.07)	($0.07)
Q4 2018	1	$0.20	$0.20	$0.20

(Data provided by Zacks Investment Research)

Dividend History for Codexis (NASDAQ:CDXS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Codexis (NASDAQ:CDXS)

Insider Ownership Percentage: 9.80%
Institutional Ownership Percentage: 63.62%

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Insider Trades by Quarter for Codexis (NASDAQ:CDXS)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/14/2017	Ventures Vii Affiliates F Vivo	Major Shareholder	Sell	1,060,000	$5.78	$6,126,800.00
11/15/2016	Patrick Y Yang	Director	Buy	10,000	$4.83	$48,300.00
9/8/2016	Ventures Fund Vii L.P. Vivo	Major Shareholder	Sell	111,600	$4.25	$474,300.00
8/29/2016	Dennis P Wolf	Director	Sell	18,000	$4.22	$75,960.00
8/24/2016	Bernard J Kelley	Director	Sell	12,643	$4.26	$53,859.18
8/16/2016	Ventures Fund Vii L.P. Vivo	Major Shareholder	Sell	86,894	$4.25	$369,299.50
8/15/2016	Vivo Ventures Vii, Llc	Major Shareholder	Sell	50,000	$4.27	$213,500.00
8/4/2016	Ventures Fund Vii L.P. Vivo	Major Shareholder	Sell	80,000	$4.22	$337,600.00
11/11/2015	James Lalonde	SVP	Sell	9,441	$3.52	$33,232.32
9/11/2015	Patrick Y Yang	Director	Buy	10,000	$3.47	$34,700.00
9/10/2015	Bernard J. Kelley	Director	Sell	5,200	$3.45	$17,940.00
8/24/2015	Patrick Y Yang	Director	Buy	10,000	$3.84	$38,400.00
8/14/2015	Patrick Y Yang	Director	Buy	20,000	$3.97	$79,400.00
6/15/2015	Dennis P Wolf	Director	Sell	35,416	$4.10	$145,205.60
11/18/2014	Patrick Y Yang	Director	Buy	20,000	$2.35	$47,000.00
11/17/2014	Patrick Y Yang	Director	Buy	20,000	$2.34	$46,800.00
8/12/2014	Patrick Y Yang	Director	Buy	60,000	$2.22	$133,200.00
3/8/2013	John J Nicols	CEO	Buy	27,000	$2.42	$65,340.00
3/7/2013	John J Nicols	CEO	Buy	54,000	$2.22	$119,880.00
3/4/2013	David D O'toole	CFO	Buy	10,000	$2.02	$20,200.00
11/12/2012	David D O'toole	CFO	Buy	5,000	$2.20	$11,000.00
9/14/2012	David D O'toole	CFO	Buy	5,000	$2.78	$13,900.00
9/14/2012	Douglas T Sheehy	SVP	Sell	3,800	$2.76	$10,488.00

(Data available from 1/1/2013 forward)

Headline Trends for Codexis (NASDAQ:CDXS) Latest Headlines for Codexis (NASDAQ:CDXS)

Source:

Date	Headline
	Codexis (CDXS) & Bio-Techne Corp (TECH) Head to Head Analysis www.americanbankingnews.com - September 20 at 2:22 PM
	Codexis, Inc. (CDXS) Major Shareholder Ventures Vii Affiliates F. Vivo Sells 1,060,000 Shares www.americanbankingnews.com - September 18 at 10:26 PM
	Comparing Codexis (CDXS) and Its Rivals www.americanbankingnews.com - September 17 at 10:32 PM
	$10.00 Million in Sales Expected for Codexis, Inc. (CDXS) This Quarter www.americanbankingnews.com - September 10 at 5:40 AM
	Codexis (CDXS) Presents At 24th Annual NewsMakers In The Biotech Industry - Slideshow seekingalpha.com - September 9 at 9:44 PM
	-$0.14 Earnings Per Share Expected for Codexis, Inc. (CDXS) This Quarter www.americanbankingnews.com - September 8 at 2:20 PM
	Codexis, Inc. (CDXS) Given Consensus Rating of "Hold" by Brokerages www.americanbankingnews.com - September 6 at 2:28 AM
	Codexis, Inc. (CDXS) Downgraded to "Sell" at Zacks Investment Research www.americanbankingnews.com - September 4 at 6:22 PM
	Codexis, Inc. (CDXS) Upgraded to Hold by ValuEngine www.americanbankingnews.com - September 3 at 7:08 PM
	Codexis to Present at Four Investment Conferences in September finance.yahoo.com - August 31 at 4:58 PM
	Codexis, Inc. (CDXS) Upgraded at BidaskClub www.americanbankingnews.com - August 19 at 7:46 PM
	3 Stocks Set to Pop www.fool.com - August 16 at 2:24 PM
	Financial Comparison: Codexis (NASDAQ:CDXS) & Repros Therapeutics (RPRX) www.americanbankingnews.com - August 14 at 8:06 PM
	Codexis, Inc. (NASDAQ:CDXS) Rating Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - August 14 at 6:38 PM
	Q3 2017 EPS Estimates for Codexis, Inc. (NASDAQ:CDXS) Lowered by Jefferies Group www.americanbankingnews.com - August 14 at 3:34 AM
	HC Wainwright Analysts Give Codexis, Inc. (NASDAQ:CDXS) a $8.00 Price Target www.americanbankingnews.com - August 13 at 3:32 PM
	Codexis, Inc. (NASDAQ:CDXS) Receives Consensus Recommendation of "Hold" from Brokerages www.americanbankingnews.com - August 12 at 2:32 AM
	Jefferies Group Brokers Reduce Earnings Estimates for Codexis, Inc. (CDXS) www.americanbankingnews.com - August 11 at 1:22 PM
	Edited Transcript of CDXS earnings conference call or presentation 9-Aug-17 8:30pm GMT finance.yahoo.com - August 10 at 6:17 PM
	Codexis, Inc. (CDXS) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS www.americanbankingnews.com - August 9 at 11:16 PM
	Codexis reports 2Q loss finance.yahoo.com - August 9 at 10:18 PM
	Codexis Reports Financial Results for the Second Quarter of 2017 finance.yahoo.com - August 9 at 5:14 PM
	Codexis (CDXS) Says Court Ordered Summary Judgment of Patent Infringement against EnzymeWorks www.streetinsider.com - August 9 at 2:53 AM
	Codexis Obtains Court Order Awarding Summary Judgment of Patent Infringement against EnzymeWorks finance.yahoo.com - August 8 at 4:47 PM
	Zacks: Brokerages Expect Codexis, Inc. (NASDAQ:CDXS) Will Post Quarterly Sales of $10.04 Million www.americanbankingnews.com - August 4 at 7:45 AM
	Zacks: Analysts Expect Codexis, Inc. (CDXS) to Announce -$0.13 Earnings Per Share www.americanbankingnews.com - August 2 at 6:23 PM
	Codexis to Hold 2017 Second Quarter Conference Call on August 9 feeds.benzinga.com - August 2 at 8:21 AM
	BidaskClub Downgrades Codexis, Inc. (NASDAQ:CDXS) to Hold www.americanbankingnews.com - July 29 at 7:56 PM
	Codexis, Inc. (CDXS) Upgraded by Zacks Investment Research to "Buy" www.americanbankingnews.com - July 19 at 8:34 PM
	Codexis, Inc. (NASDAQ:CDXS) Receives Consensus Rating of "Hold" from Brokerages www.americanbankingnews.com - July 18 at 1:45 PM
	$10.04 Million in Sales Expected for Codexis, Inc. (CDXS) This Quarter www.americanbankingnews.com - July 13 at 11:04 AM
	Codexis, Inc. (CDXS) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - July 11 at 6:40 PM
	ETFs with exposure to Codexis, Inc. : July 11, 2017 finance.yahoo.com - July 11 at 6:04 PM
	Analysts Anticipate Codexis, Inc. (CDXS) Will Post Earnings of -$0.13 Per Share www.americanbankingnews.com - July 11 at 12:22 PM
	Codexis, Inc. (NASDAQ:CDXS) Downgraded by ValuEngine to Sell www.americanbankingnews.com - July 9 at 12:02 AM
	ETFs with exposure to Codexis, Inc. : June 26, 2017 finance.yahoo.com - June 26 at 4:54 PM
	Codexis, Inc. (CDXS) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - June 21 at 10:38 PM
	Codexis, Inc. (CDXS) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - June 21 at 4:42 PM
	Analysts Anticipate Codexis, Inc. (CDXS) Will Post Quarterly Sales of $10.04 Million www.americanbankingnews.com - June 17 at 9:50 AM
	ETFs with exposure to Codexis, Inc. : June 16, 2017 finance.yahoo.com - June 16 at 4:58 PM
	Codexis, Inc. :CDXS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 15, 2017 finance.yahoo.com - June 15 at 5:59 PM
	-$0.13 Earnings Per Share Expected for Codexis, Inc. (CDXS) This Quarter www.americanbankingnews.com - June 15 at 10:50 AM
	Codexis, Inc. (CDXS) Forecasted to Earn Q2 2017 Earnings of ($0.14) Per Share www.americanbankingnews.com - June 2 at 7:18 AM
	Codexis, Inc. (CDXS) Coverage Initiated at Jefferies Group LLC www.americanbankingnews.com - May 31 at 7:38 AM
	Codexis to Present at Two Upcoming Investment Conferences finance.yahoo.com - May 30 at 12:07 PM
	Zacks Investment Research Lowers Codexis, Inc. (CDXS) to Sell www.americanbankingnews.com - May 23 at 6:16 PM
	HC Wainwright Analysts Give Codexis, Inc. (CDXS) a $8.00 Price Target www.americanbankingnews.com - May 13 at 6:58 PM
	Edited Transcript of CDXS earnings conference call or presentation 9-May-17 8:30pm GMT finance.yahoo.com - May 10 at 8:28 AM
	Codexis, Inc. (CDXS) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS www.americanbankingnews.com - May 9 at 9:22 PM
	Codexis reports 1Q loss marketbeat.com - May 9 at 7:04 PM